BOTHELL, Wash. -- ID Biomedical announced that it has been awarded up to $8 million from the U.S. National Institutes of Health (NIH) to develop a nasally delivered plague vaccine based upon the company's proprietary, intranasal, Proteosome adjuvant/delivery technology. The primary aim of this work is to develop a sub-unit plague vaccine using a recombinant plague antigen, the FIV protein, formulated with the Proteosome technology. The NIH-funded program includes preclinical and early stage clinical trials in which the vaccine's safety and immunogenicity will be studied. The long-term objective is to advance a recombinant sub-unit nasal plague vaccine to licensure in the United States.
Potential advantages of an intranasally delivered Protesome-based plague vaccine include: ease of administration which would allow for rapid immunization of large civilian populations, the ability of the vaccine to very rapidly generate immune responses which are protective and the ability of the vaccine to generate a more robust immune response by stimulating a strong immune response on the surfaces of the nose, throat and lungs, the entry site of aerosolized biothreat agents, as well as in the bloodstream.
Commenting on the award, ID Biomedical's president Todd Patrick said, "This is an important contract because it adds to a wealth of assets that we have in biodefense. We have the strategic intent of exploiting these assets to maximize the value of our company, without diverting attention from our other commercial activities. Further, this is of particular importance to leverage the work we have completed in the injectable plague vaccine development program we are pursuing with our partner, DynPort Vaccine Company. We expect to take advantage of the systems and expertise that have been developed in the injectable program and bring them to the development of a 'second-generation' plague vaccine that can be delivered intranasally."
About Plague
The Plague is an infectious disease caused by the bacterium Yersinia Pestis. There have been more than 150 recorded plague epidemics or pandemics. It is recognized as a major potential bioterrorism threat if it is spread in the air (aerosolized) because when the bacterium is inhaled into the lungs it causes an aggressive pneumonia that is nearly always fatal. Human-to-human infection occurs when a person with plague pneumonia coughs and spreads the bacteria into the air, which is then inhaled by others. Diagnosis of plague pneumonia is difficult because early symptoms are similar to the flu. There is currently no licensed plague vaccine in the United States. The development of plague vaccines is addressed in the NIH's National Institute of Allergy and Infectious Diseases' Strategic Plan for Biodefense Research. Plague vaccine development is one of six priority research areas intended to accelerate the creation of new products to combat bioterrorism.
Source: ID Biomedical
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.